Blue Jet Healthcare Inaugurates Advanced R&D Centre in Hyderabad to Accelerate Green Chemistry and Pharmaceutical Innovation

Date:

Share post:

Blue Jet Healthcare Ltd, a prominent global contract development and manufacturing organization (CDMO), has officially inaugurated its state-of-the-art Research and Development (R&D) Centre in Hyderabad. The new facility marks a critical strategic step in strengthening the company’s scientific capabilities and advancing the future of pharmaceutical chemistry. 

Designed to serve as a hub for cutting-edge chemical research, the Hyderabad R&D Centre is focused on the exploration of emerging technologies, innovative chemistries, and sustainable manufacturing approaches. By integrating modern scientific methods, the facility will accelerate the company’s efforts to build smarter, more efficient, and environmentally responsible solutions tailored for the evolving global pharmaceutical landscape.

The opening of this advanced center highlights Blue Jet Healthcare’s core commitment to scientific excellence, continuous research innovation, and long-term sustainable growth. As demand increases across the pharmaceutical and CDMO sectors for responsible manufacturing, the Hyderabad site will play a key role in developing greener chemical processes that minimize environmental impact while optimizing production scale.

“This new facility reflects our dedication to pushing scientific boundaries and working to transform complex chemistry into meaningful possibilities,” the company stated. “With smarter processes and a firm focus on greener chemistry, we are building solutions for a healthier tomorrow.”

The expansion further reinforces Blue Jet Healthcare’s position as a trusted partner for global innovators, supporting the discovery and scalable development of complex pharmaceutical intermediates, active ingredients, and advanced chemical solutions.

Written by: Pragna Biswas

Graphics by: Pramit Hazra

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related articles

ViiV Healthcare Advances HIV Care with Breakthrough Long-Acting Injectable Data at AIDS 2026

ViiV Healthcare, the global specialist HIV company majority-owned by GSK plc, announced landmark clinical, real-world, and pipeline data...

Wockhardt Launches “Wockhardt Antibiotic Academy” to Tackle Growing Threat of Multidrug Resistance in India

Wockhardt Limited announced the launch of the Wockhardt Antibiotic Academy, a national initiative dedicated to fostering patient-centric scientific dialogue...

Optimus Pharma Secures Regulatory Approval for Non-Steroidal Tapinarof Cream to Treat Plaque Psoriasis

Optimus Pharma, a leading Indian pharmaceutical manufacturer and subsidiary of Sekhmet Pharmaventures, announced that it has received regulatory...

Enhertu Shows Better Results Than Standard Treatment in Lung Cancer Trial

AstraZeneca and Daiichi Sankyo announced that their antibody-drug conjugate Enhertu (trastuzumabderuxtecan) has achieved a statistically significant and clinically meaningful improvement...